Compare Remitly Global Inc (RELY) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Remitly Global Inc vs Revvity Inc — how do they compare? Remitly Global Inc trades at $23.46 (market cap $4.98B), while Revvity Inc trades at $154.33 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 3.4× Remitly Global Inc's market cap, and Revvity Inc pays a 0.18% dividend while Remitly Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Remitly Global Inc for 53 Days and Revvity Inc for 12 Days on average.
| RELY | RVTY | |
|---|---|---|
Market Cap | $4.98B | $16.98B |
Volume | 3,501,150 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $26.92 | $157.36 |
52-Week Low | $12.20 | $82.26 |
Typical Hold Time | 53 Days | 12 Days |
Enterprise Value | $4.34B | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RELY trades at $22.93, down 1.16% on the day, with a bullish technical signal from moving averages. The company shows strong fundamental momentum, with Q2 2026 revenue growth of 20% to $495 million and three consecutive quarterly EPS beats. Analyst consensus is strongly bullish with a $30.50 price target, supported by expanding profit margins and active customer growth exceeding 10 million.
Outlook remains positive given robust revenue growth and profitability expansion, but risks include competitive pressures in fintech and reliance on continued customer acquisition. The stock offers upside to analyst targets, though volatility may persist amid market shifts.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).
The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
